A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration

AAO Journal Archive

Classification of Vitreous Seeds in Retinoblastoma
Topical 5-Fluorouracil 1% as Primary Treatment for Ocular Surface Squamous Neoplasia
Individualized Stabilization Criteria–Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion
Correlation of Histologic Features with In Vivo Imaging of Reticular Pseudodrusen
Pseudodrusen and Incidence of Late Age-Related Macular Degeneration in Fellow Eyes in the Comparison of Age-Related Macular Degeneration Treatments Trials
Pharmacotherapies for Retinal Detachment
Can Automated Imaging for Optic Disc and Retinal Nerve Fiber Layer Analysis Aid Glaucoma Detection?
Suture Colonization Rate in Adjustable Strabismus Surgery
Genetic and Dietary Factors Influencing the Progression of Nuclear Cataract
Diagnostic Accuracy of Optical Coherence Tomography and Scanning Laser Tomography for Identifying Glaucoma in Myopic Eyes

Details: October 21, 2015

To assess the safety and tolerability of E10030 (Fovista; Ophthotech, New York, NY), a platelet-derived growth factor (PDGF) antagonist, when administered in combination with an anti-vascular endothelial growth factor (VEGF) agent, ranibizumab (Lucentis; Genentech, South San Francisco, CA) 0.5 mg, by intravitreal injection in participants with neovascular age-related macular degeneration (NVAMD).

Read full article on AAO Journal

AAO Journal Archive

A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration

Member Login

AAO News

AAO Education